You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for Sulopenem


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Sulopenem?

Sulopenem is an investigational drug.

There have been 7 clinical trials for Sulopenem. The most recent clinical trial was a Phase 3 trial, which was initiated on September 18th 2018.

The most common disease conditions in clinical trials are Communicable Diseases, Infections, and Infection. The leading clinical trial sponsors are Iterum Therapeutics, International Limited, Iterum Therapeutics, US Limited, and Pfizer.

There are one hundred and thirty-two US patents protecting this investigational drug and seven hundred and thirty-four international patents.

Recent Clinical Trials for Sulopenem
TitleSponsorPhase
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult WomenIterum Therapeutics, International LimitedPhase 3
Safety, Tolerability, and Pharmacokinetics of Sulopenem in AdolescentsIterum Therapeutics, International LimitedPhase 1
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in AdultsIterum Therapeutics, International LimitedPhase 3

See all Sulopenem clinical trials

Clinical Trial Summary for Sulopenem

Top disease conditions for Sulopenem
Top clinical trial sponsors for Sulopenem

See all Sulopenem clinical trials

US Patents for Sulopenem

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sulopenem ⤷  Sign Up Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX) ⤷  Sign Up
Sulopenem ⤷  Sign Up Use of gelsolin to treat infections The Brigham and Women's Hospital, Inc. (Boston, MA) ⤷  Sign Up
Sulopenem ⤷  Sign Up Compositions and methods for delivering an agent to a wound UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (Memphis, TN) ⤷  Sign Up
Sulopenem ⤷  Sign Up Oral appliance for delivering a medicament ⤷  Sign Up
Sulopenem ⤷  Sign Up Method for using novel hydroxamic acid derivative and antibacterial substance in combination TOYAMA CHEMICAL CO., LTD. (Shinjuku-ku, JP) ⤷  Sign Up
Sulopenem ⤷  Sign Up Pharmaceutical agents and methods relating thereto Cushing Academy (Ashburnham, MA) ⤷  Sign Up
Sulopenem ⤷  Sign Up Compounds and their use ALLECRA THERAPEUTICS GMBH (Lorrach, DE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sulopenem

Drugname Country Document Number Estimated Expiration Related US Patent
Sulopenem Australia AU2005244865 2024-05-12 ⤷  Sign Up
Sulopenem Canada CA2607686 2024-05-12 ⤷  Sign Up
Sulopenem Canada CA2860173 2024-05-12 ⤷  Sign Up
Sulopenem China CN1980694 2024-05-12 ⤷  Sign Up
Sulopenem Denmark DK1755661 2024-05-12 ⤷  Sign Up
Sulopenem European Patent Office EP1755661 2024-05-12 ⤷  Sign Up
Sulopenem European Patent Office EP2335722 2024-05-12 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.